Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dSrQCfbwoceMfWqhFZNM

September 25, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • BIO raises concerns about audit of FDA drug review process
    A draft requirement that an audit of the drug review process be subject to revision based on FDA feedback raises concerns that other stakeholders could be closed out of the feedback process, BIO and PhRMA told the agency in comments on the draft. Steps should be taken to ensure the independence of the auditor, according to BIO's feedback to the agency. FDAnews/The QMN Weekly Bulletin (9/21) LinkedInFacebookTwitterEmail this Story
LES Meeting: Network with Top Licensing & BD Execs 10/14-17 in Toronto!
Meet your next partner and connect with execs from Bayer, Lilly, GSK, Merck, Pfizer, Roche, Shire, Takeda and more! Featuring Dr. Eric Topol on the Convergence of Life Sciences and High Tech plus sessions on royalty rates, dealmaking and more. Save $100 with code BIONews. Register now!
  Health Care & Policy 
  • Valeant buys QLT's eye drug Visudyne for $112.5M
    Valeant Pharmaceuticals acquired QLT's Visudyne, a treatment for abnormal growth of leaky blood vessels in the eye because of wet age-related macular degeneration. Valeant paid $112.5 million for U.S. rights, available inventory and royalty rights outside the country. Drug Store News (9/24) LinkedInFacebookTwitterEmail this Story
  • Amgen's bone drug Xgeva works against giant-cell tumor in study
    Amgen's osteoporosis treatment Xgeva, or denosumab, elicited tumor response in 86% of patients with giant-cell tumor of the bone during a midstage study. The drug, also marketed as Prolia, cut the proportion of densely cellular RANKL-positive tumor stromal cells in the tumor region and replaced them with new bone in 65% of patients. MedPage Today (free registration) (9/22) LinkedInFacebookTwitterEmail this Story
  • Stem cells in blood play role in intestines
    Stem cells called endothelial colony-forming cells are capable of traveling to the intestine and adding to the cell populations there, indicating that they could help treat inflammatory bowel disease, researchers reported in the journal Hepatology. The blood, bone marrow and cord blood contain endothelial colony-forming cells. Yahoo!/Asian News International (9/23) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Global Developments 
  • Saudi government invests $93M in biotechnology projects
    The Saudi government has spent more than $93 million on biotechnology research in the past three years, said Prince Turki bin Saud bin Mohammad Al-Saud, the chief of research at King Abdulaziz City for Science and Technology, during a biotech conference in Riyadh. Al-Saud added that KACST is collaborating with several local and international groups to develop biotechnology in the country. MENAFN.com (Jordan) (9/23) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  Featured Content 
 

  Food & Agriculture 
  Industrial & Environmental 
  • Scientists study biofuel potential of sweet sorghum
    Scientists at the Department of Agriculture's Agricultural Research Service say sweet sorghum has attributes that make it a good feedstock for biofuels. Sweet sorghum can tolerate parched conditions and requires minimal nitrogen fertilizer, making it a promising bioenergy crop for drought-prone areas, the ARS's Scott Sattler and Jeff Pedersen said. DomesticFuel.com (9/24) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
The highest reward for a person's toil is not what they get for it, but what they become by it."
--John Ruskin,
British art critic


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information